The next project meeting is planned to be held in the first quarter of 2021. More information will be available soon.
The first UHDpulse workshop for stakeholders is preliminary planned for September 2021. It will be held in connection with the 3rd FLASH workshop and the workshop for the INSPIRE project.
EURAMET website of the Project is here.
UHDpulse – Metrology for advanced radiotherapy using particle beams with ultra-high pulse dose rates is a joint research project within the European Metrology Programme for Innovation and Research (EMPIR). The project began on 1 September 2019 and will run for three years, finishing on 31 August 2022. The overall goal of the project is to provide the metrological tools needed to establish traceability in absorbed dose measurements of particle beams with ultra-high pulse dose rates (UHPDR), i.e. with ultra-high dose per pulse or with ultrashort pulse duration. The project is coordinated by the National Metrology Institute of Germany, PTB.
Download Publishable Summary of the project.
The specific objectives are:
- To develop a metrological framework, including SI-traceable primary and secondary reference standards and validated reference methods for dosimetry measurements for particle beams with ultra-high pulse dose rates.
- To characterise the response of available detector systems in particle beams with ultra-high dose per pulse or with ultrashort pulse duration.
- To develop traceable and validated methods for relative dosimetry and for the characterisation of stray radiation outside the primary pulsed particle beams.
- Using the results from objectives 1-3, to provide the input data for Codes of Practice for absolute dose measurements in particle beams with ultra-high pulse dose rates.
- To facilitate the uptake of the project’s achievements by the measurement supply chain, standards developing organisations (e.g. those associated with International Atomic Energy Agency (IAEA) and International Commission on Radiation Units (ICRU) reports) and end users (clinical and academic laboratories, hospitals and radiotherapy manufacturers).
More detailed results from reports internal to the project may be made available to individual enquirers.